Collin Blakely, MD, PhD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
ORCID ORCID Icon0000-0001-8134-3651 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of WashingtonB.S.1997Molecular and Cellular Biology
    University of PennsylvaniaPh.D.2006Cell and Molecular Biology
    University of PennsylvaniaM.D.2007Medicine
    University of Pennsylvania Health SystemResidency2009Internal Medicine
    UCSFFellowship2011Medical Oncology
    Collapse Awards and Honors
    Damon Runyon Cancer Research Foundation2018  - 2021Damon Runyon Clinical Investigator Award
    Doris Duke Charitable Foundation2018  - 2012Clinical Scientist Award
    V Foundation2018  - 2020V Scholar Award
    AACR2014  - 2016AACR BioOncology Fellowship
    Uniting Against Lung Cancer2014  - 2016Legacy Award
    Bonnie J. Addario Lung Cancer Foundation2013Research Grant

    Collapse Overview 
    Collapse Overview
    Dr. Blakely is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-, and ALK-targeted therapies, and identifying new targets for molecular-directed therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discov. 2022 Jul 27. Noronha A, Belugali Nataraj N, Sang Lee J, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. PMID: 35895872.
      View in: PubMed   Mentions:    Fields:    
    2. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J Clin Invest. 2022 07 01; 132(13). Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG. PMID: 35579943; PMCID: PMC9246391.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    3. Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Sci Transl Med. 2022 03 30; 14(638):eabc7480. Ali M, Lu M, Ang HX, Soderquist RS, Eyler CE, Hutchinson HM, Glass C, Bassil CF, Lopez OM, Kerr DL, Falcon CJ, Yu HA, Hata AN, Blakely CM, McCoach CE, Bivona TG, Wood KC. PMID: 35353542; PMCID: PMC9516479.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    4. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 12; 19(12):1441-1464. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. PMID: 34902832.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    5. Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. J Vis Exp. 2021 11 22; (177). Barbosa Rabago D, Blakely CM, Haderk F, Bivona TG. PMID: 34866626.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study. J Am Geriatr Soc. 2022 01; 70(1):136-149. Wong ML, Shi Y, Smith AK, Miaskowski C, Boscardin WJ, Cohen HJ, Lam V, Mazor M, Metzger L, Presley CJ, Williams GR, Loh KP, Ursem CJ, Friedlander TW, Blakely CM, Gubens MA, Allen G, Shumay D, Walter LC. PMID: 34611887; PMCID: PMC8742783.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021 11; 22(6):587-595. Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. PMID: 34544620.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021 Nov; 17(31):4045-4055. Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. PMID: 34278827; PMCID: PMC8530153.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    9. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clin Res Rep. 2021 Feb; 2(2):100114. Yang JC, Reckamp KL, Kim YC, Novello S, Smit EF, Lee JS, Su WC, Akerley WL, Blakely CM, Groen HJM, Bazhenova L, Carcereny Costa E, Chiari R, Hsia TC, Golsorkhi T, Despain D, Shih D, Popat S, Wakelee H. PMID: 34589984; PMCID: PMC8474221.
      View in: PubMed   Mentions: 2  
    10. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2020 09 01; 3(9):e209750. Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS. PMID: 32997124; PMCID: PMC7527870.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    11. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 09 03; 182(5):1232-1251.e22. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. PMID: 32822576; PMCID: PMC7484178.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    12. Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies. Clin Cancer Res. 2020 07 15; 26(14):3499-3500. Blakely CM, McCoach CE. PMID: 32366673.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. J Thorac Dis. 2020 May; 12(5):2883-2895. Gini B, Thomas N, Blakely CM. PMID: 32642201; PMCID: PMC7330397.
      View in: PubMed   Mentions: 7  
    14. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):271-282. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators. PMID: 31838007; PMCID: PMC7461630.
      View in: PubMed   Mentions: 232     Fields:    Translation:Humans
    15. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC. Expert Rev Anticancer Ther. 2019 12; 19(12):1061-1075. Blakely CM, Riess JW. PMID: 31809604.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    16. A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations. Clin Cancer Res. 2019 12 15; 25(24):7269-7271. Blakely CM. PMID: 31611281.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. PMID: 31548343; PMCID: PMC6980768.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    18. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Curr Oncol Rep. 2019 02 26; 21(3):21. Halliday PR, Blakely CM, Bivona TG. PMID: 30806814.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    19. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Res. 2019 02 01; 79(3):546-556. Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG. PMID: 30538120; PMCID: PMC6359944.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    20. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019 01; 25(1):111-118. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. PMID: 30478424; PMCID: PMC6324945.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansAnimalsCells
    21. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clin Lung Cancer. 2019 03; 20(2):e137-e141. Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. PMID: 30553716.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    22. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec; 13(12):1818-1831. Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. PMID: 30268698.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    23. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 09; 20(9):1064-1073. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG. PMID: 30104724; PMCID: PMC6115280.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansAnimalsCells
    24. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 06 15; 24(12):2758-2770. McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. PMID: 29599410; PMCID: PMC6157019.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    25. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 01 17; 29(1):96-103. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. PMID: 29125731; PMCID: PMC5773933.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    26. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. PMID: 29106415; PMCID: PMC5709185.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansCells
    27. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 01; 19(1):58-64. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. PMID: 28645632.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    28. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 03 13; 7:44206. Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. PMID: 28287179; PMCID: PMC5347024.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    29. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2017 01; 49(1):87-96. Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG. PMID: 27869830; PMCID: PMC5195898.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    30. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clin Lung Cancer. 2016 09; 17(5):466-469. McCoach CE, Bivona TG, Blakely CM, Doebele RC. PMID: 27378174; PMCID: PMC5378381.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    31. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. PMID: 26301689; PMCID: PMC4734742.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCells
    32. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 07; 11(1):98-110. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. PMID: 25843712; PMCID: PMC4394036.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCells
    33. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2012 Oct; 2(10):872-5. Blakely CM, Bivona TG. PMID: 23071030; PMCID: PMC3475614.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    34. Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011 Oct; 11(10):1607-18. Blakely C, Jahan T. PMID: 21999134.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    35. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res. 2006 Jun 15; 66(12):6421-31. Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA. PMID: 16778221.
      View in: PubMed   Mentions: 47     Fields:    Translation:AnimalsCells
    36. Developmental stage determines the effects of MYC in the mammary epithelium. Development. 2005 Mar; 132(5):1147-60. Blakely CM, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, Chodosh LA. PMID: 15689376.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    37. P52rIPK regulates the molecular cochaperone P58IPK to mediate control of the RNA-dependent protein kinase in response to cytoplasmic stress. Biochemistry. 2002 Oct 01; 41(39):11878-87. Gale M, Blakely CM, Darveau A, Romano PR, Korth MJ, Katze MG. PMID: 12269832.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    38. The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation. J Biol Chem. 2002 Sep 27; 277(39):36109-17. Tan SL, Tareen SU, Melville MW, Blakely CM, Katze MG. PMID: 12138106.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    39. Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A. Virology. 2000 Dec 20; 278(2):501-13. Katze MG, Kwieciszewski B, Goodlett DR, Blakely CM, Neddermann P, Tan SL, Aebersold R. PMID: 11118372.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    40. Tissue specific expression of PKR protein kinase in aging B6D2F1 mice. Mech Ageing Dev. 2000 Mar 13; 114(2):123-32. Ladiges W, Morton J, Blakely C, Gale M. PMID: 10799709.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals
    41. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol. 1998 Sep; 18(9):5208-18. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. PMID: 9710605; PMCID: PMC109106.
      View in: PubMed   Mentions: 193     Fields:    Translation:AnimalsCells
    42. Regulation of interferon-induced protein kinase PKR: modulation of P58IPK inhibitory function by a novel protein, P52rIPK. Mol Cell Biol. 1998 Feb; 18(2):859-71. Gale M, Blakely CM, Hopkins DA, Melville MW, Wambach M, Romano PR, Katze MG. PMID: 9447982; PMCID: PMC108797.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    Collin's Networks
    Concepts (281)
    Derived automatically from this person's publications.
    _
    Co-Authors (65)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _